Literature DB >> 20812151

The role of tau kinases in Alzheimer's disease.

Philip J Dolan1, Gail V W Johnson.   

Abstract

A principal feature of the progression of Alzheimer's disease (AD) is the appearance of aberrant phosphorylation of the microtubule-associated protein tau in the brains of affected individuals. Significant research efforts have been directed at identifying the kinases involved in this process, as well as developing pharmacological agents to inhibit these molecules. This review focuses on recent developments in both the physiological and pathological effects of tau phosphorylation, and the contribution of phosphorylation to tau toxicity and pathological progression in AD. The evolving concepts of the roles tau plays in cellular biology, and the mechanisms by which phosphorylation regulates tau function, is reshaping the framework for the development of therapeutics targeting tau to treat AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20812151      PMCID: PMC2941661     

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  108 in total

1.  Tau binding to microtubules does not directly affect microtubule-based vesicle motility.

Authors:  Gerardo Morfini; Gustavo Pigino; Naoko Mizuno; Masahide Kikkawa; Scott T Brady
Journal:  J Neurosci Res       Date:  2007-09       Impact factor: 4.164

2.  Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein.

Authors:  Robert Porzig; David Singer; Ralf Hoffmann
Journal:  Biochem Biophys Res Commun       Date:  2007-05-07       Impact factor: 3.575

3.  Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia.

Authors:  Emmanuel Planel; Karl E G Richter; Charles E Nolan; James E Finley; Li Liu; Yi Wen; Pavan Krishnamurthy; Mathieu Herman; Lili Wang; Joel B Schachter; Robert B Nelson; Lit-Fui Lau; Karen E Duff
Journal:  J Neurosci       Date:  2007-03-21       Impact factor: 6.167

4.  Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation.

Authors:  Holly Oakley; Sarah L Cole; Sreemathi Logan; Erika Maus; Pei Shao; Jeffery Craft; Angela Guillozet-Bongaarts; Masuo Ohno; John Disterhoft; Linda Van Eldik; Robert Berry; Robert Vassar
Journal:  J Neurosci       Date:  2006-10-04       Impact factor: 6.167

5.  Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency.

Authors:  Buffie J Clodfelder-Miller; Anna A Zmijewska; Gail V W Johnson; Richard S Jope
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

6.  Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine.

Authors:  Fernanda G De Felice; Pauline T Velasco; Mary P Lambert; Kirsten Viola; Sara J Fernandez; Sergio T Ferreira; William L Klein
Journal:  J Biol Chem       Date:  2007-02-16       Impact factor: 5.157

7.  Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

Authors:  Ayodeji A Asuni; Allal Boutajangout; David Quartermain; Einar M Sigurdsson
Journal:  J Neurosci       Date:  2007-08-22       Impact factor: 6.167

8.  Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.

Authors:  Erik D Roberson; Kimberly Scearce-Levie; Jorge J Palop; Fengrong Yan; Irene H Cheng; Tiffany Wu; Hilary Gerstein; Gui-Qiu Yu; Lennart Mucke
Journal:  Science       Date:  2007-05-04       Impact factor: 47.728

9.  Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1.

Authors:  Edda Thies; Eva-Maria Mandelkow
Journal:  J Neurosci       Date:  2007-03-14       Impact factor: 6.167

10.  Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein.

Authors:  Edna Grünblatt; Melita Salkovic-Petrisic; Jelena Osmanovic; Peter Riederer; Siegfried Hoyer
Journal:  J Neurochem       Date:  2007-05       Impact factor: 5.372

View more
  77 in total

Review 1.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Caspase-Cleaved Tau Impairs Mitochondrial Dynamics in Alzheimer's Disease.

Authors:  María José Pérez; Katiana Vergara-Pulgar; Claudia Jara; Fabian Cabezas-Opazo; Rodrigo A Quintanilla
Journal:  Mol Neurobiol       Date:  2017-01-13       Impact factor: 5.590

Review 3.  Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer's disease.

Authors:  Narendran Annadurai; Khushboo Agrawal; Petr Džubák; Marián Hajdúch; Viswanath Das
Journal:  Cell Mol Life Sci       Date:  2017-06-20       Impact factor: 9.261

Review 4.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

Review 5.  Tau splicing and the intricacies of dementia.

Authors:  Athena Andreadis
Journal:  J Cell Physiol       Date:  2012-03       Impact factor: 6.384

6.  The fuzzy coat of pathological human Tau fibrils is a two-layered polyelectrolyte brush.

Authors:  Susanne Wegmann; Izhar D Medalsy; Eckhard Mandelkow; Daniel J Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-26       Impact factor: 11.205

7.  Proteomic Atlas of the Human Brain in Alzheimer's Disease.

Authors:  Justin McKetney; Rosalyn M Runde; Alexander S Hebert; Shahriar Salamat; Subhojit Roy; Joshua J Coon
Journal:  J Proteome Res       Date:  2019-02-20       Impact factor: 4.466

Review 8.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

9.  Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery.

Authors:  Xue-Yang Jiang; Ting-Kai Chen; Jun-Ting Zhou; Si-Yu He; Hong-Yu Yang; Yao Chen; Wei Qu; Feng Feng; Hao-Peng Sun
Journal:  ACS Med Chem Lett       Date:  2018-02-09       Impact factor: 4.345

10.  Gene Therapy Models of Alzheimer's Disease and Other Dementias.

Authors:  Benjamin Combs; Andrew Kneynsberg; Nicholas M Kanaan
Journal:  Methods Mol Biol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.